Skip to content

Research on Multi-omics Analysis of Blood from Pricking-Cupping Therapy and Correlation Mechanisms of Therapeutic Efficacy Based on Microfluidics and POCT Technology

Research on Multi-omics Analysis of Blood from Pricking-Cupping Therapy and Correlation Mechanisms of Therapeutic Efficacy Based on Microfluidics and POCT Technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2026000059
Enrollment
Unknown
Registered
2026-01-13
Start date
2026-02-02
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pain syndrome

Interventions

Sponsors

The Shenzhen Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Core Diseases Chronic Pain:ICD-11, = 3 months, pain severity assessed by VAS = 4 points, or accompanied by sleep disorders (PSQI = 16 points). Acute Pain: = 7 days, pain severity VAS score = 6 points, or moderate to severe pain (NRS 4-10 points), including: Acute Neuralgia: Postherpetic neuralgia, trigeminal neuralgia; Acute injuries of the musculoskeletal system: Acute lumbar sprain, stiff neck, periarthritis of the shoulder/knee during the active phase; Acute episodes of headaches: Migraine, cervicogenic headache. 2. Chinese Medicine Syndrome Differentiation In accordance with the "Diagnostic and Efficacy Criteria for Internal Diseases in Traditional Chinese Medicine" and primarily classified as excess syndrome, confirmed by 2 or more intermediate-level or above TCM physicians independently. 3. Age Range: 18-70 years old.

Exclusion criteria

Exclusion criteria: 1. Bleeding risk: Coagulation dysfunction, long-term use of anticoagulant/antiplatelet medications. 2. Systemic contraindications: Severe cardiovascular/cerebrovascular diseases, uncontrolled hypertension, active infectious diseases. 3. Special populations: Pregnancy or breastfeeding, mental disorders unable to cooperate, frailty. 4. Research interference: Participation in other clinical trials within the past 3 months prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Numerical Rating Scale;

Secondary

MeasureTime frame
Interleukin-6;Tumor Necrosis Factor-alpha;Interleukin-1ß;

Countries

China

Contacts

Public ContactRaoXiaodan

Shenzhen City Traditional Chinese Medicine Hospital

raojing929@163.com18925201711

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026